The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease
Open accessAbstract
Nonalcoholic fatty liver disease (NAFLD) has an estimated prevalence of 25% in the general population, and cirrhosis secondary to nonalcoholic steatohepatitis (NASH) is predicted to become the leading cause of liver transplantation, yet there is a lack of effective licensed treatments for these conditions. There is a close relationship between insulin resistance (IR) and NAFLD, with prevalence of NAFLD being 5‐fold higher in patients with diabetes compared to those without. IR is implicated both in pathogenesis of NAFLD and in disease progression from steatosis to NASH. Thus, modulation of IR represents a potential strategy for NAFLD treatment. This review highlights key proposed mechanisms linking IR and NAFLD, such as changes in rates of adipose tissue lipolysis and de novo lipogenesis, impaired mitochondrial fatty acid β‐oxidation (FAO), changes in fat distribution, alterations in the gut microbiome, and alterations in levels of adipokines and cytokines. Furthermore, this review will discuss the main pharmacological strategies used to treat IR in patients with NAFLD and their efficacy based on recently published experimental and clinical data. These include biguanides, glucagon‐like peptide 1 receptor (GLP‐1) agonists, dipeptidyl peptidase 4 (DPP‐4) inhibitors, peroxisome proliferator‐activated receptor (PPAR‐γ/α/δ) agonists, sodium glucose cotransporter 2 (SGLT2) inhibitors, and farnesoid X receptor (FXR) agonists, with further novel treatments on the horizon. Ideally, treatment would improve IR, reduce cardiovascular risk, and produce demonstrable improvements in NASH histology—this is likely to be achieved with a combinatorial approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“02).(21) Future research should help determine whether the effects of GLP-1 agonists on NAFLD are independent of effects on weight loss and glycemic control.”
BackgroundAdipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance
Hotamisligil, G. S., Shargill, N. S., & Spiegelman, B. M. (1993) · Science · doi:10.1126/science.7678183 · Cited by 7,518
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Self-citationA placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Self-citationBoursier, J., Mueller, O., Barret, M., Machado, M., Fizanne, L., Araujo‐Perez, F., Guy, C. D., Seed, P. C., Rawls, J. F., David, L. A., et al. (2016) · Hepatology · doi:10.1002/hep.28356 · Cited by 1,483 · cited 1×
“Patients with NAFLD have distinctive microbiomes from those without NAFLD, with the magnitude of differences correlating with disease severity.(11) In murine studies, modulation of gut microbiota with antibiotics and probiotics has been associated with improvements in IR and reductions in visceral fat.”
BackgroundRatziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Koliaki, C., Szendroedi, J., Kaul, K., Jelenik, T., Nowotny, P., Jankowiak, F., Herder, C., Carstensen, M., Krausch, M., Knoefel, W. T., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.04.004 · Cited by 1,032
Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024 · cited 11×
“A meta-analysis reported that risk of T2DM was more than 2-fold higher in patients with NAFLD than those without NAFLD (random-effects hazard ratio [HR], 2.22; 95% confidence interval [CI], 1.84-2.60), with the risk being highest in patients with NASH.”
BackgroundInfluentialSelf-citationTargher, G., Bertolini, L., Padovani, R., Rodella, S., Tessari, R., Zenari, L., Day, C., & Arcaro, G. (2007) · Diabetes Care · doi:10.2337/dc06-2247 · Cited by 992
Mudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.042 · Cited by 931 · cited 3×
“( 43 ) d id n ot o bt ai n hi st ol og y bu t r ep or te d im pr ov em en t i n no ni nv as iv e m ar ke rs o f f ib ro si s in O CA -tr ea te d gr ou ps .”
BackgroundInfluentialBolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2260 · Cited by 867
Aithal, G. P., Thomas, J. A., Kaye, P. V., Lawson, A., Ryder, S. D., Spendlove, I., Austin, A. S., Freeman, J. G., Morgan, L., & Webber, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.047 · Cited by 721 · cited 10×
“A meta-analysis reported that risk of T2DM was more than 2-fold higher in patients with NAFLD than those without NAFLD (random-effects hazard ratio [HR], 2.22; 95% confidence interval [CI], 1.84-2.60), with the risk being highest in patients with NASH.”
BackgroundInfluentialSunny, N. E., Parks, E. J., Browning, J. D., & Burgess, S. C. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.11.004 · Cited by 672
Kuchay, M. S., Krishan, S., Mishra, S. K., Farooqui, K. J., Singh, M. K., Wasir, J. S., Bansal, B., Kaur, P., Jevalikar, G., Gill, H. K., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0165 · Cited by 662
Musso, G., Cassader, M., Rosina, F., & Gambino, R. (2012) · Diabetologia · doi:10.1007/s00125-011-2446-4 · Cited by 661
Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis
Mantovani, A., Byrne, C. D., Bonora, E., & Targher, G. (2018) · Diabetes Care · doi:10.2337/dc17-1902 · Cited by 624
Ofei, F., Hurel, S., Newkirk, J., Sopwith, M., & Taylor, R. (1996) · Diabetes · doi:10.2337/diab.45.7.881 · Cited by 510
Harnois, D. (2009) · Yearbook of Gastroenterology · doi:10.1016/s0739-5930(09)79298-0 · Cited by 505
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
Armstrong, M. J., Hull, D., Guo, K., Barton, D., Hazlehurst, J. M., Gathercole, L. L., Nasiri, M., Yu, J., Gough, S. C., Newsome, P. N., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.08.038 · Cited by 456
Self-citationFrom NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
Self-citationThiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis
Musso, G., Cassader, M., Paschetta, E., & Gambino, R. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.9607 · Cited by 449
Sanyal, A. J., Mofrad, P. S., Contos, M. J., Sargeant, C., Luketic, V. A., Sterling, R. K., Stravitz, R. T., Shiffman, M. L., Clore, J., & Mills, A. S. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00457-4 · Cited by 437
Reilly, S. M., Chiang, S.-H., Decker, S. J., Chang, L., Uhm, M., Larsen, M. J., Rubin, J. R., Mowers, J., White, N. M., Hochberg, I., et al. (2013) · Nature Medicine · doi:10.1038/nm.3082 · Cited by 433
Harrison, S. A., Rinella, M. E., Abdelmalek, M. F., Trotter, J. F., Paredes, A. H., Arnold, H. L., Kugelmas, M., Bashir, M. R., Jaros, M. J., Ling, L., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30474-4 · Cited by 425
Benhamed, F., Denechaud, P.-D., Lemoine, M., Robichon, C., Moldes, M., Bertrand-Michel, J., Ratziu, V., Serfaty, L., Housset, C., Capeau, J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci41636 · Cited by 408 · cited 1×
“Furthermore, patients with NASH and SIR had lower levels of ChREBP on liver biopsy.(10) These apparently contradictory effects may be because this transcription factor is important in modulating both glycolysis and lipogenesis, and its predominant effect depends on the degree of steatosis in the surrounding environmen…”
BackgroundEffects of probiotics on nonalcoholic fatty liver disease: A meta-analysis
Ma, Y.-Y. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i40.6911 · Cited by 352
Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial
Cui, J., Philo, L., Nguyen, P., Hofflich, H., Hernandez, C., Bettencourt, R., Richards, L., Salotti, J., Bhatt, A., Hooker, J., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.021 · Cited by 326
Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis
LI, Y., LIU, L., WANG, B., WANG, J., & CHEN, D. (2013) · Biomedical Reports · doi:10.3892/br.2012.18 · Cited by 290
Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease
Porez, G., Prawitt, J., Gross, B., & Staels, B. (2012) · Journal of Lipid Research · doi:10.1194/jlr.r024794 · Cited by 286
Ito, D., Shimizu, S., Inoue, K., Saito, D., Yanagisawa, M., Inukai, K., Akiyama, Y., Morimoto, Y., Noda, M., & Shimada, A. (2017) · Diabetes Care · doi:10.2337/dc17-0518 · Cited by 279
Armstrong, M. J., Houlihan, D. D., Rowe, I. A., Clausen, W. H. O., Elbrønd, B., Gough, S. C. L., Tomlinson, J. W., & Newsome, P. N. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12149 · Cited by 250
Self-citationInsulin receptor Thr1160 phosphorylation mediates lipid-induced hepatic insulin resistance
Petersen, M. C., Madiraju, A. K., Gassaway, B. M., Marcel, M., Nasiri, A. R., Butrico, G., Marcucci, M. J., Zhang, D., Abulizi, A., Zhang, X.-M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86013 · Cited by 240
Tully, D. C., Rucker, P. V., Chianelli, D., Williams, J., Vidal, A., Alper, P. B., Mutnick, D., Bursulaya, B., Schmeits, J., Wu, X., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00907 · Cited by 237
Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport
Mudaliar, S., Polidori, D., Zambrowicz, B., & Henry, R. R. (2015) · Diabetes Care · doi:10.2337/dc15-0642 · Cited by 225
Lawitz, E. J., Coste, A., Poordad, F., Alkhouri, N., Loo, N., McColgan, B. J., Tarrant, J. M., Nguyen, T., Han, L., Chung, C., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.04.042 · Cited by 217
Shibuya, T., Fushimi, N., Kawai, M., Yoshida, Y., Hachiya, H., Ito, S., Kawai, H., Ohashi, N., & Mori, A. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13061 · Cited by 191
Shao, N., Kuang, H. Y., Hao, M., Gao, X. Y., Lin, W. J., & Zou, W. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2561 · Cited by 185
Torres, D. M., Jones, F. J., Shaw, J. C., Williams, C. D., Ward, J. A., & Harrison, S. A. (2011) · Hepatology · doi:10.1002/hep.24558 · Cited by 183
Eguchi, Y., Kitajima, Y., Hyogo, H., Takahashi, H., Kojima, M., Ono, M., Araki, N., Tanaka, K., Yamaguchi, M., Matsuda, Y., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12351 · Cited by 182
Zhang, J., Zhao, Y., Xu, C., Hong, Y., Lu, H., Wu, J., & Chen, Y. (2014) · Scientific Reports · doi:10.1038/srep05832 · Cited by 172
Sattar, N., Fitchett, D., Hantel, S., George, J. T., & Zinman, B. (2018) · Diabetologia · doi:10.1007/s00125-018-4702-3 · Cited by 168
Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial
JOY, T. R., McKenzie, C. A., Tirona, R. G., Summers, K. L., Seney, S. L., Chakrabarti, S., Malhotra, N., & Beaton, M. D. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i1.141 · Cited by 152
Ohki, T., Isogawa, A., Iwamoto, M., Ohsugi, M., Yoshida, H., Toda, N., Tagawa, K., Omata, M., & Koike, K. (2012) · The Scientific World Journal · doi:10.1100/2012/496453 · Cited by 139
Chen, C., Sun, Y.-T., Chen, J., & Chang, Y. (2001) · Molecular Pharmacology · doi:10.1124/mol.59.3.493 · Cited by 132
Pioglitazone and Risk for Bone Fracture: Safety Data from a Randomized Clinical Trial
Viscoli, C. M., Inzucchi, S. E., Young, L. H., Insogna, K. L., Conwit, R., Furie, K. L., Gorman, M., Kelly, M. A., Lovejoy, A. M., Kernan, W. N., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3237 · Cited by 124
Iwasaki, T., Yoneda, M., Inamori, M., Shirakawa, J., Higurashi, T., Maeda, S., Terauchi, Y., & Nakajima, A. (2011) · Hepatogastroenterology · doi:10.5754/hge11263 · Cited by 124
Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease
Fan, H., Pan, Q., Xu, Y., & Yang, X. (2013) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302013000900005 · Cited by 122
Gastaldelli, A., Gaggini, M., Daniele, G., Ciociaro, D., Cersosimo, E., Tripathy, D., Triplitt, C., Fox, P., Musi, N., DeFronzo, R., et al. (2016) · Hepatology · doi:10.1002/hep.28827 · Cited by 96
Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis
Filipova, E. P., Uzunova, K. H., Kalinov, K., & Vekov, T. Y. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0273-4 · Cited by 94
Yaʼacov, A. B., Mizrahi, M., Shabat, Y., Lalazar, G., Adar, T., Wong, V., Muller, B. D., Rawlin, G., & Ilan (2012) · Journal of Inflammation Research · doi:10.2147/jir.s35227 · Cited by 73
Pina, T., Armesto, S., López‐Mejías, R., et al. (2014) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12814 · Cited by 72
Seko, Y., Sumida, Y., Sasaki, K., Itoh, Y., Iijima, H., Hashimoto, T., Ishii, S., & Inagaki, N. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-017-1364-8 · Cited by 71
Adar, T., Yaʼacov, A. B., Lalazar, G., Lichtenstein, Y., Nahman, D., Mizrahi, M., Wong, V., Muller, B. D., Rawlin, G., & Ilan, Y. (2011) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2011.04511.x · Cited by 69
Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes
Clarke, G. D., Solis-Herrera, C., Molina-Wilkins, M., Martinez, S., Merovci, A., Cersosimo, E., Chilton, R. J., Iozzo, P., Gastaldelli, A., Abdul-Ghani, M., et al. (2017) · Diabetes Care · doi:10.2337/dc17-0078 · Cited by 63
Fukuhara, T., Hyogo, H., Ochi, H., Fujino, H., Kan, H., Naeshiro, N., Honda, Y., Miyaki, D., Kawaoka, T., Tsuge, M., et al. (2014) · PubMed · Cited by 63
Xin, F., Zhao, Z., Zhang, R.-N., Pan, Q., Gong, Z., Sun, C., & Fan, J. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i18.2203 · Cited by 44
Association between Hemoglobin Glycation Index and NAFLD in Chinese Nondiabetic Individuals
Hu, D.-S., Zhu, S.-H., Xu, L., Chen, Q., Lin, C., Fang, D., & Wu, J.-S. (2019) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2019/8748459 · Cited by 19
Reducing endogenous insulin is linked with protection against hepatic steatosis in mice
Akheruzzaman, M., Hegde, V. K., Shin, A. C., et al. (2020) · Nutrition and Diabetes · doi:10.1038/s41387-020-0114-9 · Cited by 13
Cited by
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Trends in insulin resistance: insights into mechanisms and therapeutic strategy
Li, M., Chi, X., Wang, Y., Setrerrahmane, S., Xie, W., & Xu, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01073-0 · Cited by 939
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
Self-citationRole of Insulin Resistance in MAFLD
Sakurai, Y., Kubota, N., Yamauchi, T., & Kadowaki, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084156 · Cited by 448
How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?
Geng, Y., Faber, K. N., de Meijer, V. E., Blokzijl, H., & Moshage, H. (2021) · Hepatology International · doi:10.1007/s12072-020-10121-2 · Cited by 432
Metadata
- Authors
- Khan, R. S., Bril, F., Cusi, K., & Newsome, P. N.
- Venue
- Hepatology
- Published
- 2019-07-19
- Volume
- 70
- Issue
- 2
- Pages
- 711-724
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2905282109
- Cited by
- 542
- References
- 63
- FWCI
- 25.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.